Header Image

Latest News

Latest News

Filter Releases
 
Latest News
Date Title and Summary View
Sep 3, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the Morgan Stanley Global Healthcare Conference in Ne...
Aug 8, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2013. "The fact that we met all of our goals for the BCX4161 Phase 1 trial and secured government funding for the peramivir ...
Aug 5, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the underwriters of its recent public offering of its common stock have exercised in full their option to purchase an additional 600,000 shares. The total gross proceeds from this offering to BioCrys...
Aug 1, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2013 financial results will be released on Thursday, August 8, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial re...
Jul 31, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price to the public of $4.40 per share. The gross proceeds from this offering to BioCryst are expected ...
Jul 30, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering for a tota...
Jul 23, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Fred E. Cohen, M.D., D.Phil., was elected to the Company's Board of Directors. "The Board of Directors and Leadership Team of BioCryst are very pleased to have Fred join the ...
Jul 22, 2013
BioCryst initiating a Phase 2a trial in hereditary angioedema patients in 2013 Management to discuss results during conference call at 8:30 a.m. Eastern Time RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (...
Jul 11, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Biomedical Advanced Research and Development Authority (BARDA/HHS) has released funding under the current $234.8 million contract to enable completion of a New Drug Application (NDA) fili...
Jul 1, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the 8th Annual JMP Securities Healthcare Conference i...
May 9, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences: ...
May 7, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2013. "We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for ...
Apr 23, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2013 financial results will be released on Tuesday, May 7, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results...
Apr 16, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has completed its Type C meeting regarding intravenous (i.v.) peramivir with the U.S. Food & Drug Administration (FDA) and has received final meeting minutes. The minutes of the meeting we...
Apr 1, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration (FDA) that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory ap...
Page: First Previous
...
...
Next Last